Study identification

EU PAS number

EUPAS1000000757

Study ID

1000000757

Official title and acronym

DARWIN EU® - Multiple myeloma: patient characterisation, treatments, and survival in the period 2012–2024

DARWIN EU® study

Yes

Study countries

Denmark
Finland
France
Germany
Norway
Spain
Sweden

Study description

Multiple myeloma is a rare type of blood cancer with an estimated overall crude and age-standardized incidence rate of 6.7 and 2.8 per 100,000 persons in 2022 in Europe, respectively.
Survival rates have improved in recent years due to advancement in disease management and the introduction of new therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies. However, unmet needs for new medicines remain for the patients who do not respond to current therapies.
The rarity of multiple myeloma poses challenges across Europe in obtaining a comprehensive understanding of patient characteristics at the time of diagnosis, the different therapies administered in subsequent treatment lines, and overall survival. This study aims to address these gaps, which are important from a regulatory point of view to provide context and help understand the added value of the newest medicines under development or recently approved.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Contact details

Guido van Leeuwen

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
EMA
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable